| Big Day. Big Movers in Bio - JAZZ, HEB, MNTA, MBLX and OCLS | | Print | |
| Written by M.E.Garza | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thursday, 25 June 2009 13:35 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hemispherx BioPharma, Inc (AMEX:HEB) -- Hemispherx Biopharma says that low turnout at its annual shareholders meeting yesterday has prompted an extension until July 28 of a vote to increase the number of common-stock shares by 75 percent. Only about 40 percent of the outstanding shares entitled to vote were represented in person or by proxy during yesterday's meeting, but a majority vote is needed to approve increasing the number of shares from 200 million to 350 million, the company said. The shareholders meeting was the focus of a great deal of attention yesterday and shares traded up to $2.40 +0.39 (19.40%) after a couple of minor news items killed rumors, soothed nerves and gave investors renewed confidence in the company. As a matter of fact, I will post an interesting interview with a "citizen reporter" who kept his fellow investors on various social media forums up to date with information from that meeting via his laptop. He will share more about some of the things he observed there later tonight on BioMedReports. Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Last Trade: 11.32 +1.48 (15.04%) -- At first glance, it looks like this biotechnology company specializing in the characterization and engineering of complex drugs is climbing on no news, but subscribers to our Upcoming FDA Decision Calendar know that Momenta Pharma's partner, the Sandoz division of Novartis (NVS), filed an abbreviated new drug application (ANDA) for a generic version (M356) of Teva Pharma's (TEVA) multiple sclerosis drug Copaxone (glatiramer acetate injection) ($2.3B in sales for 2008). Chatter and developments on that front are likely bringing volume to the stock. Metabolix, Inc. (NASDAQ:MBLX) $8.56 +1.03, shares rose (13.68%) after a key development yesterday. The company announced that Newell Rubbermaid will purchase their Mirel bioplastic injection molding grade under a supply agreement. On Monday, Metabolix announced that Telles, its joint venture with Archer Daniels Midland Company that produces Mirel bioplastics, has collaborated with Teknor Color Company to develop a range of color concentrates for use with Mirel resin. The newly developed color concentrates are formulated using Mirel base resins and meet ASTM D6400 and EN 13432 standards for compostability and biodegradability. Metabolix also announced that Telles, the joint venture between Metabolix, Inc. and Archer Daniels Midland Company that produces Mirel bioplastics, has developed its injection molding bioplastic, Mirel P1003, in a collaborative effort with Nypro, a leading global precision plastics molder. Another company that moved today, was Oculus Innovative Sciences, Inc. (NASDAQ:OCLS). Yesterday, shares rose as much as 19% and today they climbed another 8.31% to close at $3.52 +0.27. On Wednesday, the biopharmaceutical company released test results conducted by an independent laboratory which indicated that their specific Microcyn Technology formulation reduced infectivity of the swine flu virus after 30-seconds exposure. It turns out that the company may have confirmed the effectiveness of in a virucidal time-kill suspension test as a way of responding to criticism from TheStreet.Com's Adam Feuerstein. I'm in the process of lining-up an interview with the techonolgy's inventor- CEO Hoji Alimi so we can get his take on these events. I encourage and invite OCLS investors to submit questions that you may have for Mr. Alimi in the comments section of this article and I will keep you posted with more on this developing story. In the meantime, here are the rest of the Healthcare Sectors Top Winners and Losers for Thursday, June 25, 1009:
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section Add this page to your favorite Social Bookmarking websites           
Set as favorite
Bookmark
Email this
Trackback(0)
Comments (6)
sallymander
said:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
After a four-day losing streak, the over all market rallied despite signs that Americans are still struggling to find jobs. A weekly report from the Labor Department said that the number of workers filing initial claims for unemployment benefits increased by 15,000 in the week ended June 20. The healthcare sector, which has been performing well despite intense recession pressure, was joined today by some action in housing stocks- this after real estate markets like California and home builders like Lennar reported a jump in sales and orders.
TrackBack URI for this entry
Subscribe to this comment's feed|
... Please ask the CEO of Oculus if he would consider a lawsuit against Adam Feuerstein. Either Feuerstein's allegations against Oculus are true or they are slander with a strong agenda. |
|
sdt1
said:
|
... Here's a few questions for Hoji. What is the general status of the Phase III trials? · Is the company moving this trial forward? If so, how, what’s the schedule, expected FDA submission, response period and estimated approval? Are patient groups being formed yet? · Are the anticipated “clearances” just more label claims or are they something else? · Label expansion is good, but shouldn’t the Phase III open up more revenue streams? What is the strategy with the label expansion vs. Phase III? · Is it correct to assume that the label expansions are an effort to build some revenue to pay for the Phase III? · Are there any staff concerns moving through the Phase III trials? · What is the lack of the Phase III approval preventing Oculus from doing? Lastly, does Hoji think thestreet's articles and timing are suspicious in controlling the price of the stock for shorters? |
|
M.E.Garza
said:
|
... Thanks to everyone who submitted questions both here and via email. We'll certainly address them with during our interview. |
|
H. Grant
said:
|
... My I suggest that you go to OCLS Yahoo message board, and read my comments and questions and researched links. Much work was done and posted on that message board. It would save you time by looking at those readily referenced sources. |
|
Sign Up For Phone Alerts
